SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
M&A analysis: Merck and Gilead splash the cash
The groups spend big on Terns and Arcellx.
Takeda aims at Bristol and Merck
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
SABCS 2025 – Gilead hasn’t given up on its Ascent
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
